Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th
NewsCompany to host an investor conference call and webcast at 4:30pm EDT
NEW YORK—March 11, 2024—Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic pharmaceutical technology company, today announced that the Company will release…
Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery
NewsApproval based on nearly 9 out of 10 patients achieving complete absence of post-surgical pain and 6 out of 10 achieving total absence of inflammation within 15 days post-ocular surgery
Eyenovia plans to launch in the U.S. as soon as this…
Eyenovia Announces FDA Approval of Redwood City as Commercial Manufacturing Facility
NewsRedwood City, California to complement Eyenovia’s facility in Reno, Nevada as well as its contract manufacturer, Coastline International, to produce commercial supply of Mydcombi
NEW YORK— February 13, 2024—Eyenovia, Inc. (NASDAQ:…
Eyenovia Re-Acquires Development And Commercialization Rights To Micropine In The U.S. And Canada
NewsMicroPine, currently in late phase III for pediatric progressive myopia, to complement Eyenovia’s commercial-stage asset, Mydcombi, as well as its pre-PDUFA candidate, APP13007
Part of corporate strategy to expedite commercialization of advanced…
Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update
NewsAcquired U.S. commercial rights to APP13007, currently under FDA review for post-surgical ocular pain and inflammation, from Formosa Pharmaceuticals
Announced FDA approval of Coastline International as contract manufacturer for Mydcombi…
Eyenovia Announces FDA Approval of Coastline International as Contract Manufacturer to Initiate Mydcombi Commercial Production
NewsAnticipates having product available to ship in January 2024
NEW YORK— November 2, 2023—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of…
Eyenovia to Sponsor Course on Drug Delivery Innovation at IJCAHPO’s 51st Annual Continuing Education (ACE) Program
NewsCourse to provide ophthalmic technicians with background on the Optejet dispensing technology and training on the use of Mydcombi™ for mydriasis
NEW YORK— October 30, 2023—Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company…
Eyenovia To Present Data On Preservative-Free Microbial Integrity Of The Optejet®
NewsIn rigorous testing, the Optejet remained contaminant-free when subjected to a microbial load that exceeds typical environmental conditions.
Presentation to be made at the American Academy of Optometry’s “Academy 2023 New Orleans” Annual…
Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference
News
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the…
Eyenovia Acquires U.S. Commercial Rights To APP13007 (Clobetasol Propionate Ophthalmic Nanosuspension, 0.05%) From Formosa Pharmaceuticals
News
APP13007, if approved, may have an advantageous profile in dosing frequency and side effects while reducing the inflammation and pain associated with ocular surgery
Further leverages Eyenovia’s Mydcombi sales force and represents additional…
Eyenovia Announces First Commercial Sale of MydCombi™
News
Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation
Validates Eyenovia’s proprietary Optejet® dispensing platform
World-renowned board-certified ophthalmologist…
Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes
News
NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing…
Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform
NewsRepresents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis
Provides critical validation of key technology that is core to Eyenovia’s proprietary development programs as well as current and future…
Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update
NewsAnnounced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023
Announced positive results from Microline Phase 3 program as a potential treatment for presbyopia and received feedback from the FDA outlining…
Eyenovia Announces Independent Director Stephen Benjamin To Step Down To Assume Role Of Head Of White House’s Office Of Public Engagement
News
NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs…
Recent Posts
- NovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare Professionals March 13, 2024
- Eyenovia to Report Fourth Quarter 2023 Results and Provide Business Update on Monday, March 18th March 11, 2024
- Eyenovia Congratulates Formosa Pharmaceuticals on FDA Approval of Clobetasol Propionate Ophthalmic Suspension 0.05% for the Treatment of Post-operative Inflammation and Pain Following Ocular Surgery March 5, 2024
Pipeline and Technology
Corporate Address
Eyenovia, Inc.
295 Madison Avenue
Suite 2400
New York, NY 10017
admin@eyenovia.com